MedAdvisor Ltd (ASX: MDR) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

MedAdvisor Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $115.10 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 377.38 million
Earnings per share -0.046
Dividend per share N/A
Year To Date Return -14.08%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

MedAdvisor Ltd (ASX: MDR)
Latest News

MDR ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About MedAdvisor Ltd

MedAdvisor Ltd is engaged in the development and deployment of the MedAdvisor medication and adherence platform. The MedAdvisor platform is focused on improving health outcomes by connecting health professionals with their patients using mobile and web technologies. It has five reporting segments: MedAdvisor; USA, UK, and Asia, and corporate. The company derives most of its revenues from MedAdvisor.

MDR Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
22 Jul 2021 $0.31 $0.00 0.00% 159,204 $0.31 $0.31 $0.31
21 Jul 2021 $0.31 $0.01 3.33% 488,114 $0.30 $0.31 $0.30
20 Jul 2021 $0.30 $0.00 0.00% 62,366 $0.31 $0.31 $0.30
19 Jul 2021 $0.30 $0.00 0.00% 77,464 $0.31 $0.31 $0.30
16 Jul 2021 $0.30 $-0.01 -3.28% 222,914 $0.31 $0.31 $0.30
15 Jul 2021 $0.31 $-0.01 -3.23% 160,200 $0.31 $0.31 $0.31
14 Jul 2021 $0.31 $0.01 3.28% 125,284 $0.31 $0.32 $0.31
13 Jul 2021 $0.31 $0.01 3.33% 149,529 $0.30 $0.31 $0.30
12 Jul 2021 $0.30 $0.00 0.00% 20,000 $0.30 $0.30 $0.30
09 Jul 2021 $0.30 $0.00 0.00% 162,022 $0.31 $0.31 $0.30
08 Jul 2021 $0.30 $-0.01 -3.23% 78,085 $0.31 $0.31 $0.30
07 Jul 2021 $0.31 $0.01 3.33% 736,555 $0.30 $0.31 $0.30
06 Jul 2021 $0.30 $0.00 0.00% 14,939 $0.30 $0.30 $0.30
05 Jul 2021 $0.30 $0.00 0.00% 77,909 $0.31 $0.31 $0.30
02 Jul 2021 $0.30 $-0.01 -3.28% 2,113,668 $0.30 $0.31 $0.30
01 Jul 2021 $0.31 $0.01 3.33% 817,451 $0.30 $0.31 $0.30
30 Jun 2021 $0.30 $-0.01 -3.28% 236,546 $0.31 $0.32 $0.30
29 Jun 2021 $0.31 $0.01 3.39% 323,871 $0.30 $0.31 $0.30
28 Jun 2021 $0.30 $-0.01 -3.33% 290,918 $0.30 $0.30 $0.30
25 Jun 2021 $0.30 $0.00 0.00% 6,093,283 $0.30 $0.30 $0.29
24 Jun 2021 $0.30 $0.01 3.39% 9,081 $0.29 $0.30 $0.29
23 Jun 2021 $0.30 $-0.01 -3.33% 233,386 $0.30 $0.31 $0.30

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
22 Dec 2020 Chris Ridd Issued 1 $2
Issue of options.
22 Dec 2020 Chris Ridd Issued 184 $70,000
Issue of securities.
22 Dec 2020 Robert Read Issued 4 $3,150
Issue of options.
18 Nov 2020 Joshua Swinnerton Issued 526 $200,000
Rights issue.
18 Nov 2020 Sandra Hook Issued 71 $27,142
Rights issue.
18 Nov 2020 Robert Read Issued 70 $26,600
Rights issue.
19 Oct 2020 Robert Read Exercise 200 $82,000
Conversion of securities. 2,014,285 - Performance Rights
19 Oct 2020 Robert Read Buy 200 $82,000
Conversion of securities.
23 Sep 2020 Robert Read Expiry 642 $286,070
Options expired.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Chris David Ridd Non-Executive ChairmanNon-Executive Director Feb 2020
Mr Ridd has 30 years experience in the IT industry including 5 years as Managing Director for Xero Australia and 15 years at Microsoft in senior executive roles. He led Xero's expansion in the Australian market from a startup to become the online cloud accounting software company.
Mr Robert Read Chief Executive OfficerManaging Director Nov 2015
Mr Read has experience in a range of businesses, including Director of Strategy and Operations in one of the world's pharmaceutical companies, GSK and roles in venture capital and private equity. He has had roles in business consultancy and senior roles in private equity including Director at ANZ Private Equity and Managing Director at Harbert Private Equity, specialising in growth of small and medium sized businesses. He brings a range of skills to the position of CEO - including leadership, sales and marketing, financial performance improvement and a understanding of the requirements to grow businesses. He is a member of Risk and People Committee.
Mr Jim Xenos Non-Executive Director Nov 2015
Mr Xenos brings to the board pharmaceuticals industry experience and market insight and forge over 25 years and have lead teams to drive outcomes. He has a record of delivering market share across national and multinational corporations by creating brand and portfolio strategies, and by introducing new product offerings that leverage go-to market platforms in industry categories. He is a member of the Risk and People Committee.
Mr Joshua Swinnerton CTOExecutive Director Nov 2015
Mr Swinnerton has experience and manage sizeable IT ventures, as a consultant, and as the technical and Operation lead of start-up companies. He led a technology start-up which he also founded and sold into the US as well as raising funds in the US for the company's expansion and managed software development. During this time he gained experience in bridging the gap between technology and business objectives.
Mr Peter Duncombe Bennetto Non-Executive Director Nov 2013
Mr Bennetto is an experienced company director, with skills in banking, corporate finance and governance. He has held company director positions in exploration, mining and manufacturing companies listed on the ASX since 1990. Mr Bennetto has been Non-Executive Chairman at MedAdvisor Limited (formerly Exalt Resources Limited) since November 28, 2013. Mr Bennetto is currently non-executive Chairman of Ironbark Zinc Ltd and Kingwest Resources Ltd. He is a member of the Risk and People Committee.
Ms Sandra Margaret Hook Non-Executive Director Jan 2016
Ms Hook has over 25 years experience which include development and implementing business and brands to drive change. She has a record in delivering customer business transformation and transitioning organisations in evolving environments. She brings financial management experience of her career which includes CEO, COO, GM, Marketing Director and Snr Brand Manager with some of Australia's media companies including News Limited, Foxtel, Federal Publishing Company, Murdoch Magazines and Fairfax. She brings a focus on customer digital innovation at Board level. Since 2000 she has served as a non-executive director on listed, public and private companies, and government bodies. She is a trustee of the Sydney Harbour Federation Trust. She is Chair of Risk Committee and a member of People Committee.
Ms Naomi Lawrie General CounselCompany Secretary Aug 2020
-
Simon Glover Chief Financial Officer
-
Steve Watt Chief Revenue Officer
-
Ruba El Afifi EGM People and Culture
-
Naomi Lawrie General CounselCompany Secretary
-
Craig Schnuriger Interim Chief Technology Officer
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Health Management Systems Inc 31,428,571 12.74%
Ebos Ph Pty Ltd 26,459,627 10.72%
Kojent Pty Ltd <Kojent A/C> 20,540,866 8.33%
HSBC Custody Nominees (Australia) Limited 16,441,606 6.66%
Wavey Industries Pty Ltd <Josh Swinnerton Family A/C> 15,008,943 6.08%
Regal Funds Management Pty Ltd 14,981,247 6.07%
Romida Enterprises Pty Ltd <Romida Family A/C> 12,992,910 5.27%
J P Morgan Nominees Australia Pty Limited 11,856,538 4.81%
Sigma Company Limited 5,952,381 2.41%
Provare Pty Ltd <Provare Investment A/C> 3,419,970 1.39%
Mishra Enterprises Pty Ltd <Mishra Family A/C> 2,894,737 1.17%
Gread Management Pty Limited <The A G & R R Family A/C> 2,631,983 1.07%
Citicorp Nominees Pty Limited 2,424,829 0.98%
HSBC Custody Nominees (Australia) Limited A/C 2 2,238,097 0.91%
Ethan Allen Investments Pty Ltd <Ethan Allen Invest Unit A/C> 2,000,000 0.81%
Dr Christopher Harold Benton 2,000,000 0.81%
National Nominees Limited 1,942,664 0.79%
Capital Concerns Pty Limited cLogue Family Super Fund A/C> 1,855,344 0.75%
Canonbar Investments Pty Ltd 1,568,964 0.64%
Mr Hamish John Hepburn 1,499,999 0.61%

Profile

since

Note